Dapagliflozin, a novel oral antidiabetic with an uncertain future

• Egile Nagusiak: Belén Escudero Vilaplana (Egilea), María José Almodóvar Carretón (Egilea), Silvia Herrero Hernández (Egilea)
• Formatua: Liburua
• Argitaratua: Elsevier, 2014-11-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Objective: Diabetes mellitus type 2 (DM2) is one of the main sociosanitary problems; there are many treatments for it. Recently, it has been approved the first drug of a new family of oral hypoglycemic agents (OHA): dapagliflozin. We aimed to review the available scientific evidence on dapagliflozin...